Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;92(8):773-801.
doi: 10.1007/s00115-021-01157-2. Epub 2021 Jul 23.

[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)]

[Article in German]
Heinz Wiendl  1   2   3 , Ralf Gold  4   5   6 , Thomas Berger  7   8   9 , Tobias Derfuss  7   8   10 , Ralf Linker  7   8   11 , Mathias Mäurer  7   8   12 , Martin Stangel  7   8   13 , Orhan Aktas  8 , Karl Baum  8 , Martin Berghoff  8 , Stefan Bittner  8 , Andrew Chan  8 , Adam Czaplinski  8 , Florian Deisenhammer  8 , Franziska Di Pauli  8 , Renaud Du Pasquier  8 , Christian Enzinger  8 , Elisabeth Fertl  8 , Achim Gass  8 , Klaus Gehring  8 , Claudio Gobbi  8 , Norbert Goebels  8 , Michael Guger  8 , Aiden Haghikia  8 , Hans-Peter Hartung  8 , Fedor Heidenreich  8 , Olaf Hoffmann  8 , Zoë R Hunter  14 , Boris Kallmann  8 , Christoph Kleinschnitz  8 , Luisa Klotz  8 , Verena Leussink  8 , Fritz Leutmezer  8 , Volker Limmroth  8 , Jan D Lünemann  8 , Andreas Lutterotti  8 , Sven G Meuth  8 , Uta Meyding-Lamadé  8 , Michael Platten  8 , Peter Rieckmann  8 , Stephan Schmidt  8 , Hayrettin Tumani  8 , Martin S Weber  8 , Frank Weber  8 , Uwe K Zettl  8 , Tjalf Ziemssen  8 , Frauke Zipp  7   8   15 ; die Multiple Sklerose Therapie Konsensus Gruppe (MSTKG)
Affiliations
Review

[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)]

[Article in German]
Heinz Wiendl et al. Nervenarzt. 2021 Aug.

Abstract
in English, German

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, Switzerland).

Die Multiple Sklerose ist eine komplexe, autoimmun vermittelte Erkrankung des zentralen Nervensystems, charakterisiert durch inflammatorische Demyelinisierung sowie axonalen/neuronalen Schaden. Die Zulassung verschiedener verlaufsmodifizierender Therapien und unser verbessertes Verständnis der Krankheitsmechanismen und -entwicklung in den letzten Jahren haben die Prognose und den Verlauf der Erkrankung deutlich verändert. Diese Aktualisierung der Behandlungsempfehlung der Multiple Sklerose Therapie Konsensus Gruppe konzentriert sich auf die wichtigsten Empfehlungen für verlaufsmodifizierende Therapien der Multiplen Sklerose im Jahr 2021. Unsere Empfehlungen basieren auf aktuellen wissenschaftlichen Erkenntnissen und gelten für diejenigen Medikamente, die in weiten Teilen Europas, insbesondere in den deutschsprachigen Ländern (Deutschland, Österreich, Schweiz), zugelassen sind.

Keywords: Autoimmune-mediated disease; Early therapeutic intervention; Guideline; Immunotherapy; Treatment recommendation.

PubMed Disclaimer

References

    1. the Scientific Advisory Board of the Swiss Multiple Sclerosis Society. the Swiss Neurological Society. Achtnichts L, Chan A, Czaplinski A, Derfuss T, Du Pasquier R, Findling O, et al. Specific aspects of immunotherapy for multiple sclerosis in Switzerland: A structured commentary. Clin Transl Neurosci. 2019;3(1):2514183X18822073.
    1. Akgün K, Kretschmann N, Haase R, Proschmann U, Kitzler HH, Reichmann H, et al. Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS. Neurol Neuroimmunol Neuroinflamm. 2019;6(3):e555. doi: 10.1212/NXI.0000000000000555. - DOI - PMC - PubMed
    1. Amato MP, Fonderico M, Portaccio E, Pastò L, Razzolini L, Prestipino E, et al. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain. 2020;143(10):3013–3024. doi: 10.1093/brain/awaa251. - DOI - PubMed
    1. Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study. Neurology. 2020;95(14):e1999–e2008. doi: 10.1212/WNL.0000000000010380. - DOI - PMC - PubMed
    1. Bar-Or A, Freedman MS, Kremenchutzky M, Menguy-Vacheron F, Bauer D, Jodl S, et al. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology. 2013;81(6):552–558. doi: 10.1212/WNL.0b013e31829e6fbf. - DOI - PMC - PubMed